Bioentrepreneur | Published:

Building for big pharma

Nature Biotechnology volume 31, pages 284287 (2013) | Download Citation

With acquisition the most likely exit for today's biotech investors, it pays to keep current with the tastes of pharmaceutical firms when launching a venture.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Big Pharma Mega-Mergers 1995–2014,

  2. 2.

    & Eur. Neuropsychopharmacol. 21, 495–499 (2011).

  3. 3.

    Tufts Center for the Study of Drug Development. Impact report: new or modified indications for existing drugs have steadily increased in U.S. 13(2) (Tufts University, March/April 2011).

  4. 4.

    Silicon Valley Bank. Continued rebound: trends in life science M&A. <> (July 2012).

  5. 5.

    Life sciences M&A sees fewer billion dollar deals. The Burrill Report (4 January 2013).

Download references

Author information

Affiliations

  1. Asiya Giniatullina is analyst, Marco Boorsma is principal and Geert-Jan Mulder is general partner at Forbion Capital Partners, Naarden, The Netherlands.

    • Asiya Giniatullina
    • , Marco Boorsma
    •  & Geert-Jan Mulder
  2. Sander van Deventer is general partner at Forbion Capital Partners and professor in the Department of Gastroenterology, Leiden University Medical Center, Leiden, The Netherlands.

    • Sander van Deventer

Authors

  1. Search for Asiya Giniatullina in:

  2. Search for Marco Boorsma in:

  3. Search for Geert-Jan Mulder in:

  4. Search for Sander van Deventer in:

Competing interests

M.B., G-J.M. and S.v.D. are employed by Forbion Capital Partners.

Corresponding author

Correspondence to Sander van Deventer.

Supplementary information

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2533

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing